New eye drug shows promise for Diabetes-Related vision loss
NCT ID NCT05301751
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2a trial tested a new biologic drug called AG-73305, given as an injection into the eye, in 25 adults with diabetic macular edema (DME), a common cause of vision loss in people with diabetes. The study aimed to check the drug's safety and how well it works over 6 months, measuring changes in vision and retinal swelling. Because it's an early-stage study with a small number of participants, the results are preliminary but will help guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AG-73305 (a biologic drug given as an eye injection)
What this could lead to
If successful, this could lead to a new treatment option for diabetic macular edema that may improve vision and reduce retinal swelling.
What could go wrong
This is a small, early-phase trial with only 25 participants, so results may not apply to everyone. The drug is injected directly into the eye, which carries risks like infection or inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center of Macula and Retina Disease
Winter Haven, Florida, 33880, United States
-
Retina Research Institute of Texas
Abilene, Texas, 79606, United States
-
Retina Vitreous Associates of Florida
St. Petersburg, Florida, 33711, United States
-
Strategic Clinical Research Group, LLC
Willow Park, Texas, 76087, United States
-
Texas Retina Associates
Fort Worth, Texas, 76104, United States
-
Valley Retina Institute
McAllen, Texas, 78503, United States